Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation

Oncotarget

Volumn 6, Issue 35, 2015, Pages 37544-37556

  Chen, XiangJian ^a   Shi, KeQing ^a   Wang, YuQun ^a   Song, Mei ^a   Zhou, Wu ^a   Tu, HongXiang ^a   Lin, Zhuo ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Colorectal cancer; MicroRNA; Robust rank aggregation; Signature

Indexed keywords

MICRORNA; MICRORNA 139 5P; MICRORNA 143 3P; MICRORNA 145 5P; MICRORNA 17 5P; MICRORNA 183 5P; MICRORNA 195 5P; MICRORNA 20A 5P; MICRORNA 21 5P; MICRORNA 378A 5P; UNCLASSIFIED DRUG; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MALE; MIDDLE AGED; PREDICTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR INVASION; VALIDATION PROCESS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947704070     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6065     Document Type: Article

References (56)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW. Colorectal cancer. Lancet. 2005; 365(9454):153-165.
3. McPhail S, Johnson S, Greenberg D, Peake M and Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015; 112 Suppl:S108-115.
4. Hu H, Krasinskas A and Willis J. Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Seminars in oncology. 2011; 38:500-510.
5. Fung KY, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, et al. Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One. 2015; 10:e0120425.
6. Zhang A, Sun H, Yan G, Wang P, Han Y and Wang X. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer letters. 2014; 345:17-20.
7. Barderas R, Babel I and Casal JI. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clinical applications. 2010; 4:159-178.
8. Berindan-Neagoe I, Monroig Pdel C, Pasculli B and Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA: a cancer journal for clinicians. 2014; 64:311-336.
9. Phuah NH and Nagoor NH. Regulation of microRNAs by natural agents: new strategies in cancer therapies. 2014; 2014:804510.
10. Vosa U, Kolde R, Vilo J, Metspalu A and Annilo T. Comprehensive meta-analysis of microRNA expression using a robust rank aggregation approach. Methods in molecular biology (Clifton, NJ). 2014; 1182:361-373.
11. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S and Zanovello P. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC genomics. 2013; 14:589.
12. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M and Pierotti MA. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Molecular cancer research: MCR. 2012; 10:504-515.
13. Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, Gentile A, Mastrodonato N, Carella M, Pellegrini F, di Sebastiano P and Andriulli A. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 2012; 7:e33663.
14. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T and Kure EH. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One. 2012; 7:e34150.
15. Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Moller S, Beissbarth T, Ried T and Litman T. The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:4919-4930.
16. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R and Slaby O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. Journal of cellular and molecular medicine. 2012; 16:2655-2666.
17. Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S and De Cecco L. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One. 2012; 7:e45105.
18. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ and Kerin MJ. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. International journal of colorectal disease. 2011; 26:1415-1422.
19. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. Journal of digestive diseases. 2010; 11:50-54.
20. Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balague O and Garcia-Foncillas J. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell research. 2008; 18:823-833.
21. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M and Garcia-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular cancer. 2006; 5:29.
22. Xu XH, Wu XB, Wu SB, Liu HB, Chen R and Li Y. Identification of miRNAs differentially expressed in clinical stages of human colorectal carcinoma-an investigation in Guangzhou, China. PLoS One. 2014; 9:e94060.
23. Liang G, Li J, Sun B, Li S, Lu L, Wang Y, Chen B and Xiao Z. Deep sequencing reveals complex mechanisms of microRNA deregulation in colorectal cancer. International journal of oncology. 2014; 45:603-610.
24. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D and Luo JH. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. The Lancet Oncology. 2013; 14:1295-1306.
25. Li X, Zhang G, Luo F, Ruan J, Huang D, Feng D, Xiao D, Zeng Z, Chen X and Wu W. Identification of aberrantly expressed miRNAs in rectal cancer. Oncology reports. 2012; 28:77-84.
26. Fu J, Tang W, Du P, Wang G, Chen W, Li J, Zhu Y, Gao J and Cui L. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC systems biology. 2012; 6:68.
27. Chen WC, Lin MS, Ye YL, Gao HJ, Song ZY and Shen XY. microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer. Experimental and therapeutic medicine. 2012; 3:1039-1048.
28. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K and Mori M. Over-and under expressed microRNAs in human colorectal cancer. International journal of oncology. 2009; 34:1069-1075.
29. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28:1385-1392.
30. Li E, Ji P, Ouyang N, Zhang Y, Wang XY, Rubin DC, Davidson NO, Bergamaschi R, Shroyer KR, Burke S, Zhu W and Williams JL. Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparities. International journal of oncology. 2014; 45:587-594.
31. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B and Wolff RK. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes, chromosomes & cancer. 2011; 50:196-206.
32. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A and Raponi M. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC cancer. 2009; 9:374.
33. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 2008; 299:425-436.
34. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B and Velculescu VE. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006; 103:3687-3692.
35. Griffith OL, Melck A, Jones SJ and Wiseman SM. Metaanalysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24:5043-5051.
36. Chan SK, Griffith OL, Tai IT and Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17:543-552.
37. Xiong B, Cheng Y, Ma L and Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. International journal of oncology. 2013; 42:219-228.
38. Peacock O, Lee AC, Cameron F, Tarbox R, Vafadar-Isfahani N, Tufarelli C and Lund JN. Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One. 2014; 9:e110267.
39. Vicinus B, Rubie C, Stegmaier N, Frick VO, Kolsch K, Kauffels A, Ghadjar P, Wagner M and Glanemann M. miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulation. Oncology reports. 2013; 30:1285-1292.
40. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. International journal of cancer Journal international du cancer. 2014; 134:1926-1934.
41. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R and Croce CM. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010; 107:21098-21103.
42. Fukushima Y, Iinuma H, Tsukamoto M, Matsuda K and Hashiguchi Y. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer. Oncology reports. 2015; 33:573-582.
43. Yamada N, Noguchi S, Mori T, Naoe T, Maruo K and Akao Y. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer letters. 2013; 335:332-342.
44. Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, Feng H, Pang W, Wang Y, Wang X, Fu Z, Liu Y, Zhao C, Zhang J, Zhang CY, Zen K, et al. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One. 2014; 9:e114420.
45. Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W and Li L. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer. 2014; 110:2300-2309.
46. Yin Y, Yan ZP, Lu NN, Xu Q, He J, Qian X, Yu J, Guan X, Jiang BH and Liu LZ. Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochimica et biophysica acta. 2013; 1829:239-247.
47. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L and Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic acids research. 2012; 40:761-774.
48. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013; 32:4806-4813.
49. Drebber U, Lay M, Wedemeyer I, Vallbohmer D, Bollschweiler E, Brabender J, Monig SP, Holscher AH, Dienes HP and Odenthal M. Altered levels of the oncomicroRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. International journal of oncology. 2011; 39:409-415.
50. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B and Meijer GA. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer. 2009; 101:707-714.
51. Luo H, Zou J, Dong Z, Zeng Q, Wu D and Liu L. Upregulated miR-17 promotes cell proliferation, tumour growth and cell cycle progression by targeting the RND3 tumour suppressor gene in colorectal carcinoma. The Biochemical journal. 2012; 442:311-321.
52. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M and Kuroda M. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer science. 2011; 102:2264-2271.
53. Cottonham CL, Kaneko S and Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. The Journal of biological chemistry. 2010; 285:35293-35302.
54. Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK, Sung JJ and Yu J. microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Molecular cancer. 2014; 13:124.
55. Wang KY, Ma J, Zhang FX, Yu MJ, Xue JS and Zhao JS. MicroRNA-378 inhibits cell growth and enhances L-OHPinduced apoptosis in human colorectal cancer. IUBMB life. 2014; 66:645-654.
56. Camp RL, Dolled-Filhart M and Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcomebased cut-point optimization. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:7252-7259.